These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23460040)

  • 41. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effectiveness and tolerance of three month sustained release leuprorelin in the treatment of metastatic prostatic cancer (comparative, randomized, multicentric study].
    Zerbib M; Lucas C; Leblanc V
    Prog Urol; 1997 Apr; 7(2):246-53. PubMed ID: 9264767
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
    Tombal B; Cornel EB; Persad R; Stari A; Gómez Veiga F; Schulman C
    J Urol; 2017 Nov; 198(5):1054-1060. PubMed ID: 28552710
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group.
    Kienle E; Lübben G
    Urol Int; 1996; 56 Suppl 1():23-30. PubMed ID: 8776814
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients.
    Shore N; Mincik I; DeGuenther M; Student V; Jievaltas M; Patockova J; Simpson K; Hu CH; Huang ST; Li Y; Lee Y; Chien B; Mao J
    World J Urol; 2020 Jan; 38(1):111-119. PubMed ID: 30941562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer.
    Fowler JE; Gottesman JE; Reid CF; Andriole GL; Soloway MS
    J Urol; 2000 Sep; 164(3 Pt 1):730-4. PubMed ID: 10953135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations.
    Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Oya M
    J Med Econ; 2017 Nov; 20(11):1155-1162. PubMed ID: 28758810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
    Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
    N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.
    Tunn UW; Wiedey K
    Prostate Cancer Prostatic Dis; 2009; 12(1):83-7. PubMed ID: 19030021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist.
    Tsushima T; Nasu Y; Saika T; Maki Y; Noda M; Suyama B; Yamato T; Kumon H
    Urol Int; 2001; 66(3):135-9. PubMed ID: 11316974
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
    Oefelein MG; Cornum R
    J Urol; 2000 Sep; 164(3 Pt 1):726-9. PubMed ID: 10953134
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate.
    Sasagawa I; Kubota Y; Nakada T; Suzuki H; Hirano J; Sugano O; Kato H; Imamura A; Mastushita K; Onmura Y; Saito M; Adachi M
    Int Urol Nephrol; 1998; 30(6):745-53. PubMed ID: 10195870
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.
    McLeod D; Zinner N; Tomera K; Gleason D; Fotheringham N; Campion M; Garnick MB;
    Urology; 2001 Nov; 58(5):756-61. PubMed ID: 11711355
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
    Crawford ED; Moul JW; Sartor O; Shore ND
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer.
    van der Sluis TM; van Moorselaar RJ; Meuleman EJ; ter Haar RW; Bui HN; Heijboer AC; Vis AN
    Urology; 2013 May; 81(5):1005-9. PubMed ID: 23465153
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer.
    Ishizuka O; Nishizawa O; Nishizawa S; Satoh T; Wajiki M; Kiyokawa H; Inoue Y; Kobayashi S; Mizusawa H; Nakagawa T
    Int J Clin Oncol; 2013 Jun; 18(3):524-30. PubMed ID: 22552359
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer.
    Perez-Marreno R; Chu FM; Gleason D; Loizides E; Wachs B; Tyler RC
    Clin Ther; 2002 Nov; 24(11):1902-14. PubMed ID: 12501882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].
    Ouzaid I; Rouprêt M
    Prog Urol; 2011 Nov; 21(12):866-74. PubMed ID: 22035913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.